Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha Vaccines – part of the Cyrus Poonawalla Group.

The acquisition includes a biologics manufacturing facility and associated assets in Bohumil, Czech Republic. The facility is expected to provide an annual capacity of over 1 billion doses of antigen starting in 2021 for Novavax’ COVID-19 vaccine candidate, NVX‑CoV2373.

NVX‑CoV2373 consists of a stable, prefusion protein antigen made using its proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M adjuvant.

The acquisition also includes a 150,000-square foot state of the art vaccine and biologics manufacturing facility and other support buildings, along with the existing employees and all related and required infrastructure.

The facility is completing a renovation that includes Biosafety Level-3 (BSL-3) capabilities. As part of the transaction, approximately 150 employees with significant experience in vaccine manufacturing and support have joined Novavax.

“Manufacturing capacity is a critical component of our strategy to deliver a vaccine for the COVID-19 pandemic,” said Stanley C. Erck, President and CEO of Novavax.

“This acquisition provides the vital assets required to produce more than 1 billion doses per year. In parallel with ramping up production at Bohumil, we will continue efforts to expand antigen capacity in the US and Asia, and increase production of Matrix-M to match antigen capacity at multiple sites globally.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Avalon GloboCare & BOKU to advance intranasal & oral COVID-19 vaccine candidate

Avalon GloboCare, a New Jersey-based clinical-stage global developer of cell-based technologies and therapeutics, has partnered with the University of Natural Resources and Life Sciences...

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...

Gilead acquires equity interest in pioneering immunotherapy company

Gilead Sciences is acquiring a 49.9% equity interest in Pionyr Immunotherapeutics, a privately held San Fran company developing first-in-class cancer immunotherapies. The acquisition – for...

New class of precision medicine strips cancer of its DNA defences

A new precision medicine targeting cancer’s ability to repair its DNA has shown promising results in the first clinical trial of the drug class. The...

Related news

Pharma industry invests £381m in UK R&D activities

The pharmaceutical industry has invested £381.2 million on R&D activities in the UK during 2019, up from £377.3 million in 2018, according to new...

Avalon GloboCare & BOKU to advance intranasal & oral COVID-19 vaccine candidate

Avalon GloboCare, a New Jersey-based clinical-stage global developer of cell-based technologies and therapeutics, has partnered with the University of Natural Resources and Life Sciences...

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...